Literature DB >> 17258675

[Drug treatment of type 2 diabetes].

Amélie Tielmans1, Marie Laloi-Michelin, Muriel Coupaye, Marie Virally, Taly Meas, Pierre-Jean Guillausseau.   

Abstract

Drug treatment of 2 diabetes is intended to normalize glycosylated hemoglobin levels (HbA(1c)<6.5%) and thereby prevent the development of micro- and macrovascular complications. Oral antidiabetic agents target the metabolic abnormalities that cause diabetes. The two principal families of oral antidiabetic agents - insulin sensitizers and insulin secretagogues - can be taken together. Thiazolidinediones or glitazones (insulin sensitizers) improve peripheral tissue sensitivity to insulin. Metformin (an insulin sensitizer) reduces hepatic glucose production. Sulfonylureas and meglitinides (insulin secretagogues) stimulate insulin secretion and can cause hypoglycemia. GLP-1 (Glucagon-Like Peptide-1) analogs and DPP-IV (dipeptidyl-peptidase-IV) inhibitors are new drug classes currently under development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17258675     DOI: 10.1016/j.lpm.2006.10.017

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  2 in total

1.  Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists.

Authors:  Lei Sun; Zhi-Ming Zheng; Chang-Sheng Shao; Zhi-Yong Zhang; Ming-Wei Li; Li Wang; Han Wang; Gen-Hai Zhao; Peng Wang
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-13

2.  Hypoglycaemic effect of Berberis vulgaris L. in normal and streptozotocin-induced diabetic rats.

Authors:  Nawel Meliani; Mohamed El Amine Dib; Hocine Allali; Boufeldja Tabti
Journal:  Asian Pac J Trop Biomed       Date:  2011-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.